Methods of inhibiting CXC intercrine molecules
AssigneeBoard of Regents, The University of Texas System
InventorsAllen Barry Cohen, deceased, Edmund J. Miller, Shinichiro Hayashi, Anna K. Kurdowska, Ronald R. Tuttle
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2.beta. binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis.
Claims59
A method of inhibiting a CXC intercrine family molecule, comprising contacting the CXC intercrine molecule or intercrine target cells with a biologically effective amount of a composition comprising a peptide of from 6 to about 14 residues in length including the amino acid sequence Arg Arg Trp Trp Cys Xaa.sub.1 (SEQ ID NO:23), wherein Xaa.sub.1 is any amino acid residue.
Dependencies are inferred from the claim text.